Xenova came under pressure to seek a merger in June 2000 when its lead drug XR5000, a topoisomerase inhibitor, proved ineffective in phase II trials in colon cancer. Shares in both companies ...

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer.

“He was very excited and said that indenoisoquinoline had the same cytotoxicity profile as some clinically useful topoisomerase I inhibitors,” says Cushman ... Already, results are promising; in one ...